Education
About Us
Working with TipRanks
Follow Us
Coeptis Therapeutics Holdings (COEP)
NASDAQ:COEP
COEP Stock Chart & Stats
$15.09
$0.24(3.56%)
At close: 4:00 PM EST
$15.09
$0.24(3.56%)
Day’s Range― - ―
52-Week Range$2.31 - $21.41
Previous Close$6.8
Volume106.19K
Average Volume (3M)40.59K
Market Cap
$80.80M
Enterprise ValueN/A
Total Cash (Recent Filing)$5.33M
Total Debt (Recent Filing)$279.87K
Price to Earnings (P/E)―
Beta0.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.65
Shares Outstanding5,340,111
10 Day Avg. Volume61,038
30 Day Avg. Volume40,592
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.4
Revenue Forecast (FY)N/A
Coeptis Therapeutics Holdings News
COEP FAQ
What was Coeptis Therapeutics Holdings’s price range in the past 12 months?
Coeptis Therapeutics Holdings lowest stock price was $2.31 and its highest was $21.41 in the past 12 months.
What is Coeptis Therapeutics Holdings’s market cap?
Coeptis Therapeutics Holdings’s market cap is $80.80M.
When is Coeptis Therapeutics Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Coeptis Therapeutics Holdings’s earnings last quarter?
Currently, no data Available
Is Coeptis Therapeutics Holdings overvalued?
According to Wall Street analysts Coeptis Therapeutics Holdings’s price is currently Overvalued.
Does Coeptis Therapeutics Holdings pay dividends?
Coeptis Therapeutics Holdings does not currently pay dividends.
What is Coeptis Therapeutics Holdings’s EPS estimate?
Coeptis Therapeutics Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Coeptis Therapeutics Holdings have?
Coeptis Therapeutics Holdings has 5,340,111 shares outstanding.
What happened to Coeptis Therapeutics Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Coeptis Therapeutics Holdings?
Currently, no hedge funds are holding shares in COEP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coeptis Therapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.80%
12-Months-Change
Fundamentals
Return on Equity
-127.31%
Trailing 12-Months
Asset Growth
47.27%
Trailing 12-Months
Company Description
Coeptis Therapeutics Holdings
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Technical Analysis
Relmada Therapeutics
―
ABVC BioPharma
―
Prelude Therapeutics
―
Werewolf Therapeutics
―
Estrella Immunopharma
―